AMANTADINE HYDROCHLORIDE
| Brand name | OSMOLEX ER |
|---|---|
| Active ingredient | AMANTADINE HYDROCHLORIDE |
| Strength | EQ 258MG BASE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | February 2018 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 10213394 | February 2038 | use U-2497 |
| 10213393 | February 2038 | use U-20 |
| 10500170 | February 2038 | use U-20 |
| 10500172 | February 2038 | use U-2497 |
| 10500171 | February 2038 | use U-2497 |
| 10512617 | February 2038 | use U-2497 |
| 8252331 | March 2030 | product |
| 8389578 | January 2028 | use U-3054 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.